CCLD Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 11.67% compared to CareCloud's net margin of -1.05%. CareCloud's return on equity of 17.63% beat Astrana Health's return on equity of 9.13%.

CareCloud has a consensus price target of $4.44, signalling upside risk potential of 135.54%. On the other hand Astrana Health has an analysts' consensus of $50.5000 which suggests that it could grow by 55.43%. Given that CareCloud has higher upside potential than Astrana Health, analysts believe CareCloud is more attractive than Astrana Health.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Astrana Health has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.209%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CareCloud quarterly revenues are $28.2M, which are smaller than Astrana Health quarterly revenues of $665.2M. CareCloud's net income of $3.3M is higher than Astrana Health's net income of -$7M. Notably, CareCloud's price-to-earnings ratio is -- while Astrana Health's PE ratio is 36.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.27x versus 0.77x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of 11.67% compared to CareCloud's net margin of 7.43%. CareCloud's return on equity of 17.63% beat Biote's return on equity of --.

CareCloud has a consensus price target of $4.44, signalling upside risk potential of 135.54%. On the other hand Biote has an analysts' consensus of $7.47 which suggests that it could grow by 114.56%. Given that CareCloud has higher upside potential than Biote, analysts believe CareCloud is more attractive than Biote.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

CareCloud quarterly revenues are $28.2M, which are smaller than Biote quarterly revenues of $49.8M. CareCloud's net income of $3.3M is lower than Biote's net income of $3.7M. Notably, CareCloud's price-to-earnings ratio is -- while Biote's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.27x versus 0.61x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 11.67% compared to CareCloud's net margin of 3.55%. CareCloud's return on equity of 17.63% beat Cryo-Cell International's return on equity of --.

CareCloud has a consensus price target of $4.44, signalling upside risk potential of 135.54%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 75.26%. Given that CareCloud has higher upside potential than Cryo-Cell International, analysts believe CareCloud is more attractive than Cryo-Cell International.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 10.31% to investors and pays a quarterly dividend of $0.25 per share. CareCloud pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

CareCloud quarterly revenues are $28.2M, which are larger than Cryo-Cell International quarterly revenues of $8M. CareCloud's net income of $3.3M is higher than Cryo-Cell International's net income of $282.9K. Notably, CareCloud's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 485.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.27x versus 1.24x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 11.67% compared to CareCloud's net margin of -12.84%. CareCloud's return on equity of 17.63% beat P3 Health Partners's return on equity of -26.35%.

CareCloud has a consensus price target of $4.44, signalling upside risk potential of 135.54%. On the other hand P3 Health Partners has an analysts' consensus of $16.25 which suggests that it could grow by 84.66%. Given that CareCloud has higher upside potential than P3 Health Partners, analysts believe CareCloud is more attractive than P3 Health Partners.

CareCloud has a beta of 2.047, which suggesting that the stock is 104.714% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CareCloud has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CareCloud pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

CareCloud quarterly revenues are $28.2M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. CareCloud's net income of $3.3M is higher than P3 Health Partners's net income of -$46.5M. Notably, CareCloud's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CareCloud is 0.27x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.